Cargando…

Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment

SIMPLE SUMMARY: Thyroid carcinoma is the most common cancer of the endocrine system and accounts for 12% of all cancer cases in adolescents in the United States. In this paper, we present a double-blind, randomized, placebo-controlled clinical trial aimed at evaluating the effect of probiotics suppl...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortazavi, Seyed Mohammad Javad, Nowroozi, Saba, Haghani, Masoud, Zarrini-Monfared, Zinat, Gheisari, Farshid, Sihver, Lembit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913142/
https://www.ncbi.nlm.nih.gov/pubmed/36765697
http://dx.doi.org/10.3390/cancers15030740
_version_ 1784885352990769152
author Mortazavi, Seyed Mohammad Javad
Nowroozi, Saba
Haghani, Masoud
Zarrini-Monfared, Zinat
Gheisari, Farshid
Sihver, Lembit
author_facet Mortazavi, Seyed Mohammad Javad
Nowroozi, Saba
Haghani, Masoud
Zarrini-Monfared, Zinat
Gheisari, Farshid
Sihver, Lembit
author_sort Mortazavi, Seyed Mohammad Javad
collection PubMed
description SIMPLE SUMMARY: Thyroid carcinoma is the most common cancer of the endocrine system and accounts for 12% of all cancer cases in adolescents in the United States. In this paper, we present a double-blind, randomized, placebo-controlled clinical trial aimed at evaluating the effect of probiotics supplementation in reducing the acute side-effects of radioiodine therapy in DTC patients. The probiotics’ effectiveness was confirmed for dry mouth and taste loss or change when it was administered prior to the radioiodine treatment. The benefit was not confirmed for other radiation-induced complications such as pain and swelling in the neck, nausea and vomiting, salivary gland swelling, and diarrhea. Further large-scale clinical trials are warranted to improve our knowledge of this quickly evolving field. ABSTRACT: Thyroid carcinoma is the most common cancer of the endocrine system, accounting for 12% of all cancer cases in adolescents in the United States. Radioiodine therapy plays a key role in differentiated thyroid cancer (DTC) treatment. This double-blind, randomized, placebo-controlled clinical trial was aimed at evaluating the effect of probiotics supplementation in reducing the acute side-effects of radioiodine therapy in PTC patients. Fifty-six patients were randomly divided into four groups: one placebo and three intervention groups. The probiotics product used in this study was LactoCare (ZistTakhmir Co., Tehran, Iran), a multi-strain commercially available symbiotic containing 12 strains of probiotic species including Lactobacillus strains, Bifidobacteria strains, and Streptococcus thermophilus, plus Fructo-oligosaccharides as the prebiotic. Group 0 was our placebo group (no probiotics), while the other three groups received probiotics capsules for 2/4 days, starting only 2 days prior to radioiodine therapy, only 4 days after radioiodine therapy or 2 days prior and 4 days after radioiodine therapy. Six patients were withdrawn during the study because of poor compliance or at their own request. The symptoms reported by patients including data about the incidence and duration of each complication were recorded. The probiotics’ effectiveness was confirmed for dry mouth and taste loss or change when it was administered prior to the radioiodine treatment. The benefit was not confirmed for other radiation-induced complications such as pain and swelling in the neck, nausea and vomiting, salivary gland swelling, and diarrhea. Further large-scale clinical trials are warranted to improve our knowledge in this quickly evolving field.
format Online
Article
Text
id pubmed-9913142
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99131422023-02-11 Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment Mortazavi, Seyed Mohammad Javad Nowroozi, Saba Haghani, Masoud Zarrini-Monfared, Zinat Gheisari, Farshid Sihver, Lembit Cancers (Basel) Article SIMPLE SUMMARY: Thyroid carcinoma is the most common cancer of the endocrine system and accounts for 12% of all cancer cases in adolescents in the United States. In this paper, we present a double-blind, randomized, placebo-controlled clinical trial aimed at evaluating the effect of probiotics supplementation in reducing the acute side-effects of radioiodine therapy in DTC patients. The probiotics’ effectiveness was confirmed for dry mouth and taste loss or change when it was administered prior to the radioiodine treatment. The benefit was not confirmed for other radiation-induced complications such as pain and swelling in the neck, nausea and vomiting, salivary gland swelling, and diarrhea. Further large-scale clinical trials are warranted to improve our knowledge of this quickly evolving field. ABSTRACT: Thyroid carcinoma is the most common cancer of the endocrine system, accounting for 12% of all cancer cases in adolescents in the United States. Radioiodine therapy plays a key role in differentiated thyroid cancer (DTC) treatment. This double-blind, randomized, placebo-controlled clinical trial was aimed at evaluating the effect of probiotics supplementation in reducing the acute side-effects of radioiodine therapy in PTC patients. Fifty-six patients were randomly divided into four groups: one placebo and three intervention groups. The probiotics product used in this study was LactoCare (ZistTakhmir Co., Tehran, Iran), a multi-strain commercially available symbiotic containing 12 strains of probiotic species including Lactobacillus strains, Bifidobacteria strains, and Streptococcus thermophilus, plus Fructo-oligosaccharides as the prebiotic. Group 0 was our placebo group (no probiotics), while the other three groups received probiotics capsules for 2/4 days, starting only 2 days prior to radioiodine therapy, only 4 days after radioiodine therapy or 2 days prior and 4 days after radioiodine therapy. Six patients were withdrawn during the study because of poor compliance or at their own request. The symptoms reported by patients including data about the incidence and duration of each complication were recorded. The probiotics’ effectiveness was confirmed for dry mouth and taste loss or change when it was administered prior to the radioiodine treatment. The benefit was not confirmed for other radiation-induced complications such as pain and swelling in the neck, nausea and vomiting, salivary gland swelling, and diarrhea. Further large-scale clinical trials are warranted to improve our knowledge in this quickly evolving field. MDPI 2023-01-25 /pmc/articles/PMC9913142/ /pubmed/36765697 http://dx.doi.org/10.3390/cancers15030740 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mortazavi, Seyed Mohammad Javad
Nowroozi, Saba
Haghani, Masoud
Zarrini-Monfared, Zinat
Gheisari, Farshid
Sihver, Lembit
Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment
title Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment
title_full Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment
title_fullStr Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment
title_full_unstemmed Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment
title_short Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment
title_sort probiotic bacteria cannot mitigate the adverse effects of radioactive iodine-131 treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913142/
https://www.ncbi.nlm.nih.gov/pubmed/36765697
http://dx.doi.org/10.3390/cancers15030740
work_keys_str_mv AT mortazaviseyedmohammadjavad probioticbacteriacannotmitigatetheadverseeffectsofradioactiveiodine131treatment
AT nowroozisaba probioticbacteriacannotmitigatetheadverseeffectsofradioactiveiodine131treatment
AT haghanimasoud probioticbacteriacannotmitigatetheadverseeffectsofradioactiveiodine131treatment
AT zarrinimonfaredzinat probioticbacteriacannotmitigatetheadverseeffectsofradioactiveiodine131treatment
AT gheisarifarshid probioticbacteriacannotmitigatetheadverseeffectsofradioactiveiodine131treatment
AT sihverlembit probioticbacteriacannotmitigatetheadverseeffectsofradioactiveiodine131treatment